The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ADCT | +44.77% | -84.72% | -31.32% | -85% |
| S&P | +18.33% | +108.18% | +15.79% | +141% |
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $18.84M | 8.2% |
| Gross Profit | $17.16M | 11.8% |
| Gross Margin | 91.10% | 2.9% |
| Market Cap | $265.80M | -12.6% |
| Market Cap / Employee | $1.00M | 0.0% |
| Employees | 265 | 63.6% |
| Net Income | -$56.65M | -55.0% |
| EBITDA | -$30.22M | -7.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $264.56M | -11.8% |
| Accounts Receivable | $26.18M | 14.5% |
| Inventory | 17.8 | 16.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $448.98M | 265.1% |
| Short Term Debt | $1.79M | 26.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -49.02% | 0.1% |
| Return On Invested Capital | 185.91% | 59.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$27.62M | 12.6% |
| Operating Free Cash Flow | -$27.61M | 12.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.31 | -1.12 | -0.69 | -1.12 | -17.05% |
| Price to Sales | 4.67 | 2.96 | 1.99 | 3.95 | -12.89% |
| Price to Tangible Book Value | -2.31 | -1.12 | -0.69 | -1.12 | -17.05% |
| Enterprise Value to EBITDA | -5.19 | -2.59 | -14.94 | -16.25 | 261.85% |
| Total Debt | $124.55M | $123.00M | $456.81M | $450.77M | 262.36% |
ADCT earnings call for the period ending June 30, 2022.
ADCT earnings call for the period ending March 31, 2022.
ADCT earnings call for the period ending December 31, 2021.
ADCT earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
